Repurposing Nucleoside Analogs for Human Coronaviruses

Coronavirus disease 2019 (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed confirmation. Here, we evaluated a panel of compounds and identified no...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Antimicrobial agents and chemotherapy Ročník 65; číslo 1
Hlavní autori:	Zandi, Keivan, Amblard, Franck, Musall, Katie, Downs-Bowen, Jessica, Kleinbard, Ruby, Oo, Adrian, Cao, Dongdong, Liang, Bo, Russell, Olivia O, McBrayer, Tamara, Bassit, Leda, Kim, Baek, Schinazi, Raymond F
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 16.12.2020
Predmet:	Animals Antiviral Agents - chemistry Antiviral Agents - pharmacology Antiviral Agents - toxicity Cell Line Chlorocebus aethiops Coronavirus OC43, Human - drug effects Drug Evaluation, Preclinical Drug Repositioning - methods Humans Nucleosides - chemistry Nucleosides - pharmacology Nucleosides - toxicity Propanolamines - pharmacology SARS-CoV-2 - drug effects Sofosbuvir - pharmacology Vero Cells COVID-19 sofosbuvir emtricitabine SARS-CoV-2 nucleoside analogs antiviral agents Coronaviridae remdesivir HCoV-OC43 lamivudine
ISSN:	1098-6596, 1098-6596
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!